157 related articles for article (PubMed ID: 25921529)
1. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
3. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
5. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
6. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
8. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
9. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
10. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 Gp120/CXCR4 axis promotes CCR7 ligand-dependent CD4 T cell migration: CCR7 homo- and CCR7/CXCR4 hetero-oligomer formation as a possible mechanism for up-regulation of functional CCR7.
Hayasaka H; Kobayashi D; Yoshimura H; Nakayama EE; Shioda T; Miyasaka M
PLoS One; 2015; 10(2):e0117454. PubMed ID: 25688986
[TBL] [Abstract][Full Text] [Related]
12. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
13. Plectin regulates the signaling and trafficking of the HIV-1 co-receptor CXCR4 and plays a role in HIV-1 infection.
Ding Y; Zhang L; Goodwin JS; Wang Z; Liu B; Zhang J; Fan GH
Exp Cell Res; 2008 Feb; 314(3):590-602. PubMed ID: 18155192
[TBL] [Abstract][Full Text] [Related]
14. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
15. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
16. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
17. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
20. Dimerization of the Peptide CXCR4-Antagonist on Macromolecular and Supramolecular Protraction Arms Affords Increased Potency and Enhanced Plasma Stability.
Harms M; Hansson RF; Carmali S; Almeida-Hernández Y; Sanchez-Garcia E; Münch J; Zelikin AN
Bioconjug Chem; 2022 Apr; 33(4):594-607. PubMed ID: 35293739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
